Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in.

about

Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab

P2860

Q26764882-D80752FF-D564-4EC8-980E-A1EAC2029D04

P2860

Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in.

Item

http://www.wikidata.org/entity/Q42822669

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in.

@en

Nonvitamin K antagonist oral anticoagulants

@nl

type

Item

label

Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in.

@en

Nonvitamin K antagonist oral anticoagulants

@nl

prefLabel

Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in.

@en

Nonvitamin K antagonist oral anticoagulants

@nl

P1476

Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in.

@en

P2093

Andrew Blann

http://www.w3.org/2001/XMLSchema#string

P2860

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome

Rivaroxaban in patients with a recent acute coronary syndrome.

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.

Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.

Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism.

The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants.

Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation.

Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.

On the treatment of new oral anticoagulant-associated gastrointestinal hemorrhage.

P304

489-492

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.2147/VHRM.S89736

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26316773

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation

P932

4548753

http://www.w3.org/2001/XMLSchema#string

Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in.

about

P2860

P2860

Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P921

P932